Enovis Announces Third Quarter 2026 Results
Board of Directors approves new $200 million share repurchase authorization Dallas, TX, November 5, 2026 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 2, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis’ third-quarter net sales of $559 million grew 2% on a reported basis and 5% on an organic basis from the same quarter in 2025. Third quarter results reflect continued execution in P&R and Recon and encouraging momentum in new product introductions. Compared to the same quarter in 2025, net sales in Recon grew 6% on a reported basis and 6% on an organic basis, and P&R declined 2% on a reported basis and grew 3% on an organic basis.
Enovis also reported a third-quarter net income of $3 million , or 0.6% of sales, and adjusted EBITDA of $104 million, or 18.5% of sales.
The Company reported third-quarter 2026 net income of $0.02 per share and adjusted net earnings per diluted share of $0.88. “Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline,” said Damien McDonald, Chief Executive Officer of Enovis. “Growth was consistent with our expectations for the quarter, with continued share gains in Recon and steady performance in Prevention & Recovery.
The environment remains dynamic, including volatility and cost inflation in many markets. Despite these challenges, we are investing in the technologies that will define the next phase of our growth, including our agreement to acquire eCential Robotics, while maintaining strong cost and capital discipline. Our focus remains on continuously improving how we operate and execute to make our performance repeatable, and increasingly profitable.”
Enovis updated financial expectations for 2026. Revenue guidance is narrowed to a range of $2.32-2.35 billion, versus prior expectations of $2.31-2.37 billion. Revenue guidance incorporates 5% organic revenue growth, as compared to 4-6% previously. Adjusted EBITDA guidance is raised to a range of $428-438 million, as compared to the prior outlook of $425-435 million. The guidance ranges for revenue
and adjusted EBITDA are based on current exchange rates. Enovis now expects foreign currency to be a benefit to revenue growth of 0.5%-1.0%, as compared to 0.5%-1.5% previously. Full-year adjusted earnings per share guidance is raised from $3.52-3.73 to $3.58-3.79. Full year free cash flow conversion is expected to be 25% or higher.
Enovis also announced that its Board of Directors has approved a new share repurchase authorization of up to $200 million of the Company’s outstanding common stock. The new authorization replaces the Company’s existing $100 million share repurchase authorization. The timing and amount of any repurchases will be determined by management based on market conditions, the Company’s capital allocation priorities and other factors.
Investors can access the webcast via a link on the Enovis website, www.enovis.com . For those planning to participate on the call, please dial (833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and asked to be joined into the Enovis call. A link to a replay of the call will also be available on the Enovis website later in the day.
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com.
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
This press release includes forward-looking statements, including forward- looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the Company’s planned acquisition of eCential and the expected timeline for completing the acquisition, the growth potential of eCential’s surgical robotics platform combined with the Company’s ARVIS® Augmented Reality System, planned funding for the acquisition, the financial and operational impact of the acquisition, including the anticipated impact on Adjusted EBITDA margins, plans, goals, objectives, outlook, expectations and intentions; Enovis’ integration of Lima; the impact of
public health emergencies and global pandemics; disruptions in the global economy caused by escalating geopolitical tensions including in connection with the ongoing conflicts between Russia and Ukraine and in the Middle East; macroeconomic conditions, including the impact of inflationary pressures; changes in government trade policies, including the implementation of tariffs ; the impact of a shutdown of the U.S. government or any future shutdowns; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.
Enovis has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations (“Adjusted net income”), Adjusted net income per diluted share, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross profit, and Adjusted gross profit margin.
Adjusted net income and Adjusted net income per diluted share exclude net income attributable to noncontrolling interest from continuing operations, net of taxes; the effect of income (loss) from discontinued operations, net of taxes; restructuring charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and property plant and equipment step-up depreciation; goodwill impairment charges; non-cash Other (income) expense, net; and include the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents Adjusted net income margin, which is subject to the same adjustments as Adjusted net income.
Adjusted EBITDA represents Adjusted net income excluding all Other (income) expense, net; interest, taxes, and depreciation and other amortization. Enovis presents Adjusted EBITDA margin, which is subject to the same adjustments as Adjusted EBITDA.
Adjusted gross profit represents gross profit excluding depreciation step-up of acquired fixed assets and the impact of restructuring charges. Adjusted gross profit margin is subject to the same adjustments as Adjusted gross profit.
Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions, divestitures, and foreign exchange rate fluctuations.
Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment net of proceeds from sale of certain properties. Free cash flow conversion represents free cash flow divided by adjusted net income.
These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on
a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.
(1) Net income (loss) from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net income (loss) from continuing operations less net income attributable to noncontrolling interest from continuing operations - net of taxes.
(2) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and $1.7 million classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 3, 2025, respectively. There were no similar charges for the three and nine months ended October 2, 2026.
(3) MDR and other costs includes (i) $0.4 million and $1.6 million for the three and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the three and nine months ended October 3, 2025, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write- offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.5 million and $1.2 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine months ended October 3, 2025, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
(4) Includes $0.6 million and $1.9 million in PPE step-up depreciation in connection with acquired businesses for the three and nine months ended October 2, 2026 and $0.7 million and $1.9 million for the three and nine months ended October 3, 2025, respectively.
(5) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for the three and nine months ended October 2, 2026 and $9.2 million and $28.1 million for the three and nine months ended October 3, 2025, respectively, related to non-recurring integration costs associated with the Lima Acquisition which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are non-recurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $6.1 million and $6.5 million for the three and nine months ended October 2, 2026 and $6.1 million and $11.8 million for the three and nine months ended October 3, 2025, of non-recurring (non-Lima) acquisition integration costs, and other non-recurring project costs for global ERP rationalization and shared service center start-up, offset by a $5.7 million non-cash gain in the second quarter of 2026 from the reversal of a portion of a contingent consideration liability (See Note 11), and (iii) $0.3 million and $0.6 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.3 million for the three and nine months ended October 3, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
(6) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.
(7) Other (income) expense, net includes the fair value gain adjustment for non- designated cross currency swaps in 2026. Includes the final fair value loss adjustment for the Contingent Acquisition Shares issued in the first quarter of 2025.
(8) The effective tax rates used to calculate adjusted net income and adjusted net income per share were 23.0% and 22.7% for the three and nine months ended October 2, 2026 and 21.8% and 22.6% for the three and nine months ended October 3, 2025.
(9) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted Net Income and Adjusted Net Income Per Diluted Share to no longer adjust for inventory step-up charges. Adjusted Net Income in prior periods has been revised to reflect this change for consistency of presentation along with its impact on the effective tax rate which has been revised from 22.9%, as presented in our Form 8-K for the nine months ended October 3, 2025, to 22.6%. Accordingly, Adjusted Net Income for the nine months ended October 3, 2025 has been revised from $135.6 million or $2.36 per diluted share, respectively, as presented in our Form 8-K for the ended October 3, 2025, to $122.1 million, or $2.12 per diluted share, respectively, reflecting the removal of a $18.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted net income margin from continuing operations for the nine months ended October 3, 2025 from 8.1%, as presented in our Form 8-K for the period ended October 3, 2025, to 7.3%. There was no adjustment for inventory step-up during the three months ended October 3, 2025 .
(1) Restructuring charges reflect costs associated with the Company’s restructuring programs to reduce the structural costs of the Company. For further information, see Note 10, “Accrued Liabilities - Accrued Restructuring Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and $1.7 million classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 3, 2025, respectively. There were no similar charges for the three and nine months ended October 2, 2026.
(2) MDR and other costs includes (i) $0.4 million and $1.6 million for the three and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the three and nine months ended October 3, 2025, respectively, in non-recurring costs specific to updating our quality system, product labeling, asset write- offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.5 million and $1.2 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine months ended October 3, 2025, respectively, of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
(3) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for the three and nine months ended October 2, 2026 and $9.2 million and $28.1 million for the three and nine months ended October 3, 2025, respectively, related to non-recurring integration costs associated with the Lima Acquisition which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are non-recurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $6.1 million and $6.5 million for the three and nine months ended October 2, 2026 and $6.1 million and $11.8 million for the three and nine months ended October 3, 2025, of non-recurring (non-Lima) acquisition integration costs, and other non-recurring project costs for global ERP rationalization and shared service center start-up, offset by a $5.7 million non-cash gain in the second quarter of 2026 from the reversal of a portion of a contingent consideration liability (See Note 11), and (iii) $0.3 million and $0.6 million for the three and nine months ended October 2, 2026 and $0.4 million and $1.3 million for the three and nine months ended October 3, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
(4) Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.
(5) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the nine months ended October 3, 2025 has been revised from $291.1 million, as presented in our Form 10-Q for the period ended October 3, 2025, to $273.0 million, reflecting the removal of a $18.1 million adjustment for inventory step-up in connection with acquired businesses resulting in a corresponding reduction to Adjusted EBITDA margin for the nine months ended October 3, 2025 from 17.4%, as presented in our Form 10-Q for the period ended October 3, 2025, to 16.3%. There was no adjustment for inventory step-up during the three months ended October 3, 2025 .
(1) In conjunction with our Form 10-Q filing for the first quarter of 2026, we revised our definition of Adjusted gross profit to no longer adjust for inventory step-up charges. Adjusted gross profit in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted gross profit for the nine months ended October 3, 2025 has been revised from $1,017.3 million, as presented in our Form 8-K for the period ended October 3, 2025, to $999.2 million, reflecting the removal of a $18.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted gross profit margin for the nine months ended October 3, 2025 from 60.8%, as presented in our Form 8-K for the period ended October 3, 2025, to 59.8%. There was no adjustment for inventory step-up during the three months ended October 3, 2025 .
Nine Months Ended October 2, 2026 October 3, 2025 ────────────────────────────────────────────────────────────────────────────── Cash flows from operating activities: Net loss $ -6,069 $ -663,166 Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and 217,884 217,366 amortization Impairment of — 548,442 goodwill Stock-based compensation 25,470 24,809 expense Non-cash 5,929 5,120 interest expense Fair value loss on contingent — 1,787 acquisition shares Deferred income -42,241 -565 tax benefit Loss on disposal of property, 960 1,129 plant and equipment Changes in operating assets and liabilities: Trade 7,588 -17 receivables, net Inventories, net -44,283 -33,153 Accounts payable 15,602 10,345 Other operating assets and -10,364 16,652 liabilities Net cash provided by 170,476 128,749 operating activities Cash flows from investing activities: Purchases of property, plant and -133,204 -141,122 equipment and intangibles Payments for acquisitions, net of cash -4,122 -26,859 received, and investments Cash received (paid) for net investment -3,283 1,601 hedge derivatives Net cash used in investing -140,609 -166,380 activities Cash flows from financing activities: Repayments of borrowings under -26,250 -15,000 term credit facility Proceeds from borrowings on revolving 172,000 177,000 credit facilities and other Repayments of borrowings on revolving -189,041 -136,862 credit facilities and other Payments of tax withholding for -1,473 -3,504 stock-based awards Proceeds from issuance of 1,354 1,318 common stock, net Deferred consideration -9,637 -2,437 payments and other Net cash provided by (used in) -53,047 20,515 financing activities Effect of foreign exchange rates on Cash -171 2,566 and cash equivalents Decrease in Cash and cash -23,351 -14,550 equivalents Cash and cash equivalents, 36,389 48,167 beginning of period Cash and cash equivalents, end $ 13,038 $ 33,617 of period
(1) Constant currency growth rate represents sales growth excluding the impact of foreign exchange rate fluctuations based on prior year sales valued at the current period foreign currency rates.
(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.
(3) The three months ended October 3, 2025 include $13.8 million of sales from the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions product line
(1) Constant currency growth rate represents sales growth excluding the impact of foreign exchange rate fluctuations based on prior year sales valued at the current period foreign currency rates.
(2) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume. (3) The nine months ended October 3, 2025 include $40.9 million of sales from the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions product line.
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions/divestitures, thus providing a measure of change due to factors such as price, product mix and volume.
(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.
(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.
(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of change due to factors such as price, product mix and volume.
(2) Represents the incremental sales as a result of acquisitions of businesses for twelve months from the acquisition date. Excludes (i) acquisitions of former distribution partners as such transactions primarily represent a shift from a third-party distribution model to a direct sales model, and (ii) acquisitions of intellectual property as such transactions involve the purchase of technologies that have not been commercialized.
(3) Represents the decrease in sales as a result of divestitures of businesses for twelve months from the divestiture date.
(4) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
Full text with the tables
Enovis Announces Third Quarter 2026 Results
•
Third-quarter sales growth of 2% on a reported basis, 5% organic
•
Third-quarter Reconstructive sales growth of 6% on a reported and organic basis
•
Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS
•
Board of Directors approves new $200 million share repurchase authorization
Dallas, TX, November 5, 2026 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or
“the Company”) (NYSE: ENOV), an innovation-driven medical technology growth
company, today announced its financial results for the third quarter ended
October 2, 2026. The Company will host an investor conference call and live
webcast to discuss these results today at 8:30 am ET.
Third Quarter 2026 Financial Results
Enovis’ third-quarter net sales of $559 million grew 2% on a reported basis and
5% on an organic basis from the same quarter in 2025. Third quarter results
reflect continued execution in P&R and Recon and encouraging momentum in new
product introductions. Compared to the same quarter in 2025, net sales in Recon
grew 6% on a reported basis and 6% on an organic basis, and P&R declined 2% on a
reported basis and grew 3% on an organic basis.
Enovis also reported a third-quarter net income of $3 million , or 0.6% of
sales, and adjusted EBITDA of $104 million, or 18.5% of sales.
The Company reported third-quarter 2026 net income of $0.02 per share and
adjusted net earnings per diluted share of $0.88.
“Our third-quarter results reflect continued progress against our innovation-led
strategy and the benefits of executing with greater alignment, accountability,
and discipline,” said Damien McDonald, Chief Executive Officer of Enovis.
“Growth was consistent with our expectations for the quarter, with continued
share gains in Recon and steady performance in Prevention & Recovery.
The environment remains dynamic, including volatility and cost inflation in many
markets. Despite these challenges, we are investing in the technologies that
will define the next phase of our growth, including our agreement to acquire
eCential Robotics, while maintaining strong cost and capital discipline. Our
focus remains on continuously improving how we operate and execute to make our
performance repeatable, and increasingly profitable.”
2026 Financial Outlook
Enovis updated financial expectations for 2026. Revenue guidance is narrowed to
a range of $2.32-2.35 billion, versus prior expectations of $2.31-2.37 billion.
Revenue guidance incorporates 5% organic revenue growth, as compared to 4-6%
previously. Adjusted EBITDA guidance is raised to a range of $428-438 million,
as compared to the prior outlook of $425-435 million. The guidance ranges for
revenue
and adjusted EBITDA are based on current exchange rates. Enovis now expects
foreign currency to be a benefit to revenue growth of 0.5%-1.0%, as compared to
0.5%-1.5% previously. Full-year adjusted earnings per share guidance is raised
from $3.52-3.73 to $3.58-3.79. Full year free cash flow conversion is expected
to be 25% or higher.
Share Repurchase Authorization
Enovis also announced that its Board of Directors has approved a new share
repurchase authorization of up to $200 million of the Company’s outstanding
common stock. The new authorization replaces the Company’s existing $100 million
share repurchase authorization. The timing and amount of any repurchases will be
determined by management based on market conditions, the Company’s capital
allocation priorities and other factors.
Conference call and Webcast
Investors can access the webcast via a link on the Enovis website,
www.enovis.com . For those planning to participate on the call, please dial
(833) 685-0901 (U.S. callers) and (412) 317-5715 (International callers) and
asked to be joined into the Enovis call. A link to a replay of the call will
also be available on the Enovis website later in the day.
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to
improving lives by developing clinically differentiated solutions that enhance
patient outcomes and restore motion for life. We partner with the brightest
minds in health to advance care that is smarter, personalized, and more
effective, while improving operational efficiency for surgeons and clinicians
around the world. Enovis solutions impact the well-being of millions of patients
wherever they are on their pathway to health. Discover more about Enovis at
www.enovis.com.
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material
information to investors and the marketplace using SEC filings, press releases,
public conference calls, webcasts and the Enovis Investor Relations website.
While not all of the information that the Company posts to the Enovis Investor
Relations website is of a material nature, some information could be deemed to
be material. Accordingly, the Company encourages investors, the media and others
interested in Enovis to review the information that it shares on ir.enovis.com.
Forward-Looking Statements
This press release includes forward-looking statements, including forward-
looking statements within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but are not limited
to, statements concerning Enovis’ plans, goals, objectives, outlook,
expectations and intentions, and other statements that are not historical or
current fact. Forward-looking statements are based on Enovis’ current
expectations and involve risks and uncertainties that could cause actual results
to differ materially from those expressed or implied in such forward-looking
statements. Factors that could cause Enovis’ results to differ materially from
current expectations include, but are not limited to, risks related to the
Company’s planned acquisition of eCential and the expected timeline for
completing the acquisition, the growth potential of eCential’s surgical robotics
platform combined with the Company’s ARVIS® Augmented Reality System, planned
funding for the acquisition, the financial and operational impact of the
acquisition, including the anticipated impact on Adjusted EBITDA margins, plans,
goals, objectives, outlook, expectations and intentions; Enovis’ integration of
Lima; the impact of
public health emergencies and global pandemics; disruptions in the global
economy caused by escalating geopolitical tensions including in connection with
the ongoing conflicts between Russia and Ukraine and in the Middle East;
macroeconomic conditions, including the impact of inflationary pressures;
changes in government trade policies, including the implementation of tariffs ;
the impact of a shutdown of the U.S. government or any future shutdowns; supply
chain disruptions; increasing energy costs and availability concerns,
particularly in the European market; other impacts on Enovis’ business and
ability to execute business continuity plans; and the other factors detailed in
Enovis’ reports filed with the U.S. Securities and Exchange Commission (the
“SEC”), including its most recent Annual Report on Form 10-K under the caption
“Risk Factors,” as well as the other risks discussed in Enovis’ filings with the
SEC. In addition, these statements are based on assumptions that are subject to
change. This press release speaks only as of the date hereof. Enovis disclaims
any duty to update the information herein.
Non-GAAP Financial Measures
Enovis has provided in this press release financial information that has not
been prepared in accordance with accounting principles generally accepted in the
United States of America (“non-GAAP”). These non-GAAP financial measures may
include one or more of the following: adjusted net income from continuing
operations (“Adjusted net income”), Adjusted net income per diluted share,
Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross profit, and Adjusted
gross profit margin.
Adjusted net income and Adjusted net income per diluted share exclude net income
attributable to noncontrolling interest from continuing operations, net of
taxes; the effect of income (loss) from discontinued operations, net of taxes;
restructuring charges; Medical Device Regulation (“MDR”) fees and other costs;
strategic transaction costs; stock-based compensation; acquisition-related
intangible asset amortization; strategic purchase of economic interest on future
royalty payments; and property plant and equipment step-up depreciation;
goodwill impairment charges; non-cash Other (income) expense, net; and include
the tax effect of adjusted pre-tax income at applicable tax rates and other tax
adjustments. Enovis also presents Adjusted net income margin, which is subject
to the same adjustments as Adjusted net income.
Adjusted EBITDA represents Adjusted net income excluding all Other (income)
expense, net; interest, taxes, and depreciation and other amortization. Enovis
presents Adjusted EBITDA margin, which is subject to the same adjustments as
Adjusted EBITDA.
Adjusted gross profit represents gross profit excluding depreciation step-up of
acquired fixed assets and the impact of restructuring charges. Adjusted gross
profit margin is subject to the same adjustments as Adjusted gross profit.
Organic sales growth calculates sales growth period over period, after excluding
the impact of acquisitions, divestitures, and foreign exchange rate
fluctuations.
Free cash flow represents cash flow from operating activities less purchases of
property, plant and equipment net of proceeds from sale of certain properties.
Free cash flow conversion represents free cash flow divided by adjusted net
income.
These non-GAAP financial measures assist Enovis management in comparing its
operating performance over time because certain items may obscure underlying
business trends and make comparisons of long-term performance difficult, as they
are of a nature and/or size that occur with inconsistent frequency or relate to
discrete restructuring plans that are fundamentally different from the ongoing
productivity improvements of the Company. Enovis management also believes that
presenting these measures allows investors to view its performance using the
same measures that the Company uses in evaluating its financial and business
performance and trends. Non-GAAP financial measures should not be considered in
isolation from, or as a substitute for, financial information calculated in
accordance with GAAP. Investors are encouraged to review the reconciliation of
these non-GAAP measures to their most directly comparable GAAP financial
measures. A reconciliation of non-GAAP financial measures presented above to
GAAP results has been provided in the financial tables included in this press
release. Enovis does not provide reconciliations of adjusted EBITDA or adjusted
earnings per share on a forward-looking basis to the closest GAAP financial
measures, as such information is not available without unreasonable efforts on
a forward-looking basis due to uncertainties regarding, and the potential
variability of, reconciling items excluded from these measures. These items are
uncertain, depend on various factors, and could have a material impact on GAAP
reported results for the guidance period.
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
[email protected]
Enovis Corporation
Condensed Consolidated Statements of Operations
Dollars in thousands, except per share data
(Unaudited)
Three Octob… Octo… Nine Octo… Octob…
Mont… 2, 3, Months 2, 3,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 558,7… $ 548,… $ 1,73… $ 1,672…
sales
Cost
of 218,8… 219,… 666,… 676,4…
sales
Gross 339,8… 328,… 1,06… 995,8…
prof…
Gross
prof… 60.8 % 59.9 % 61.5 % 59.5 %
marg…
Sell…
gene…
and 259,3… 263,… 805,… 799,7…
admi…
expe…
Rese…
and 31,275 29,7… 94,4… 88,967
deve…
expe…
Amor…
of 43,254 43,6… 126,… 128,4…
acqu…
inta…
Purc…
of — — — 45,818
roya…
inte…
Rest… 2,568 1,910 10,1… 6,488
char…
Good…
impa… — 548,… — 548,4…
char…
Oper…
inco… 3,375 -558… 27,3… -622,…
(los…
Oper…
inco… 0.6 % -101… % 1.6 % -37.2 %
(los…
marg…
Inte…
expe… 7,616 8,828 24,8… 27,310
net
Other
(inc… -3,785 -448 -5,1… 508
expe…
net
Inco…
(los…
from
cont… -456 -566… 7,643 -649,…
oper…
befo…
inco…
taxes
Inco…
tax -1,679 4,005 15,8… 13,037
expe…
(ben…
Net
inco…
(los… 1,223 -570… -8,2… -662,…
from
cont…
oper…
Inco…
(los…
from
disc… 2,194 -40 2,155 -258
oper…
net
of
taxes
Net
inco… 3,417 -570… -6,0… -663,…
(los…
Net
inco… 0.6 % -104… % -0.4 % -39.7 %
(los…
marg…
Less:
net
inco…
attr…
to
nonc…
inte… 278 233 746 685
from
cont…
oper…
- net
of
taxes
Net
inco…
(los…
attr… $ 3,139 $ -571… $ -6,8… $ -663,…
to
Enov…
Corp…
Net
inco…
(los…
per
share
-
basic
and
dilu…
Cont… $ 0.02 $ -9.99 $ -0.16 $ -11.64
oper…
Disc… $ 0.04 $ — $ 0.04 $ —
oper…
Cons… $ 0.06 $ -9.99 $ -0.12 $ -11.64
oper…
Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions, except per share data
(Unaudited)
Three Octob… Octo… Nine Octo… Octob…
Mont… 2, 3, Months 2, 3,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Adju…
Net
Inco…
and
Adju…
Net
Inco…
Per
Share
Net
inco… $ 3.4 $ -570… $ -6.1 $ -663.2
(los…
(GAA…
Net
inco…
(los… 0.6 % -104… % -0.4 % -39.7 %
marg…
(GAA…
Net
loss
attr…
to
nonc…
inte…
from -0.3 -0.2 -0.7 -0.7
cont…
oper…
-
net
of
taxes
Loss
(Inc…
from
disc… -2.2 — -2.2 0.3
oper…
net
of
taxes
Net
inco…
(los…
from
cont… $ 0.9 $ -571… $ -9.0 $ -663.6
oper…
attr…
to
Enov…
Corp…
Rest…
char… 2.6 3.4 10.1 8.2
-
pret…
MDR
and
other 0.9 2.4 2.8 9.0
costs
-
pret…
Amor…
of
acqu… 43.3 43.7 126.7 128.5
inta…
-
pret…
Good…
impa… — 548.4 — 548.4
char…
PPE
step…
depr… 0.6 0.7 1.9 1.9
-
pret…
Stra…
tran…
costs 15.6 15.7 28.1 41.2
-
pret…
Purc…
of — — — 45.8
roya…
inte…
Stoc… 7.5 9.0 25.2 25.0
comp…
Other
(inc… -2.9 -0.4 -0.6 0.5
expe…
net(…
Tax -17.1 -8.2 -30.0 -22.9
adju…
Adju…
net
inco…
from $ 51.4 $ 43.5 $ 155.2 $ 122.1
cont…
oper…
(non…
Adju…
net
inco…
marg… 9.2 % 7.9 % 9.0 % 7.3 %
from
cont…
oper…
Weig…
shar…
outs… 57,672 57,1… 57,5… 57,029
-
dilu…
(GAA…
Net
loss
per
share
- $ 0.02 $ -9.99 $ -0.16 $ -11.64
dilu…
from
cont…
oper…
(GAA…
Adju…
weig…
shar…
outs… 58,493 57,7… 58,2… 57,558
-
dilu…
(non…
Adju…
net
inco…
per
share
- $ 0.88 $ 0.75 $ 2.67 $ 2.12
dilu…
from
cont…
oper…
(non…
__________
(1) Net income (loss) from continuing operations attributable to Enovis
Corporation for the respective periods is calculated using Net income (loss)
from continuing operations less net income attributable to noncontrolling
interest from continuing operations - net of taxes.
(2) Restructuring charges reflect costs associated with the Company’s
restructuring programs to reduce the structural costs of the Company. For
further information, see Note 10, “Accrued Liabilities - Accrued Restructuring
Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and
$1.7 million classified as Cost of sales on the Company’s Condensed Consolidated
Statements of Operations for the three and nine months ended October 3, 2025,
respectively. There were no similar charges for the three and nine months ended
October 2, 2026.
(3) MDR and other costs includes (i) $0.4 million and $1.6 million for the three
and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the
three and nine months ended October 3, 2025, respectively, in non-recurring
costs specific to updating our quality system, product labeling, asset write-
offs and product remanufacturing to comply with the medical device reporting
regulations and other requirements of the new medical device regulations in the
European Union for devices which were introduced to the market prior to the
regulation and (ii) $0.5 million and $1.2 million for the three and nine months
ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine
months ended October 3, 2025, respectively, of expenses to resolve certain
infrequent, non-recurring regulatory or other legal matters. These costs are
classified as Selling, general and administrative expense on our Condensed
Consolidated Statements of Operations.
(4) Includes $0.6 million and $1.9 million in PPE step-up depreciation in
connection with acquired businesses for the three and nine months ended October
2, 2026 and $0.7 million and $1.9 million for the three and nine months ended
October 3, 2025, respectively.
(5) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for
the three and nine months ended October 2, 2026 and $9.2 million and $28.1
million for the three and nine months ended October 3, 2025, respectively,
related to non-recurring integration costs associated with the Lima Acquisition
which includes (a) payroll and retention costs for roles eliminated in
connection with the integration of our recent acquisition of Lima where a legal
notice period was required prior to the employee’s separation from the Company,
or integration-related daily activities not related to former roles performed by
an employee during their legal notice period and prior to their separation from
the Company. In each case, such costs relate solely to roles eliminated in
connection with the integration of the Lima acquisition, and are non-recurring
and not part of our normal business operations; (b) professional and consulting
fees specifically incurred to consummate the acquisition and advise and
facilitate on post-acquisition integration matters including legal entity
consolidation, costs associated with rebranding and marketing acquired business
under Enovis name, such as marketing materials, trade show redesign costs and
product labeling; and (c) integration related costs associated with sales agent
and distributor network rationalization, including contract termination and
retention expenses, supply chain and portfolio integration, and quality
management system consolidation, (ii) $6.1 million and $6.5 million for the
three and nine months ended October 2, 2026 and $6.1 million and $11.8 million
for the three and nine months ended October 3, 2025, of non-recurring (non-Lima)
acquisition integration costs, and other non-recurring project costs for global
ERP rationalization and shared service center start-up, offset by a $5.7 million
non-cash gain in the second quarter of 2026 from the reversal of a portion of a
contingent consideration liability (See Note 11), and (iii) $0.3 million and
$0.6 million for the three and nine months ended October 2, 2026 and $0.4
million and $1.3 million for the three and nine months ended October 3, 2025,
respectively, related to the Separation of our former fabrication technology
business. These costs are classified as Selling, general and administrative
expense on our Condensed Consolidated Statements of Operations.
(6) Purchase of royalty interest represents the one-time, up-front expense
incurred by the Company to acquire the economic rights to future royalties under
product development agreements in connection with the termination of such
agreements as part of a strategic shift to a new product development model. The
Company believes that excluding the impact of such expense enhances
comparability between periods, provides investors with a clear and meaningful
view of our underlying business trends and aligns with how management evaluates
the ongoing business performance.
(7) Other (income) expense, net includes the fair value gain adjustment for non-
designated cross currency swaps in 2026. Includes the final fair value loss
adjustment for the Contingent Acquisition Shares issued in the first quarter of
2025.
(8) The effective tax rates used to calculate adjusted net income and adjusted
net income per share were 23.0% and 22.7% for the three and nine months ended
October 2, 2026 and 21.8% and 22.6% for the three and nine months ended October
3, 2025.
(9) In conjunction with our Form 10-Q filing for the first quarter of 2026, we
revised our definition of Adjusted Net Income and Adjusted Net Income Per
Diluted Share to no longer adjust for inventory step-up charges. Adjusted Net
Income in prior periods has been revised to reflect this change for consistency
of presentation along with its impact on the effective tax rate which has been
revised from 22.9%, as presented in our Form 8-K for the nine months ended
October 3, 2025, to 22.6%. Accordingly, Adjusted Net Income for the nine months
ended October 3, 2025 has been revised from $135.6 million or $2.36 per diluted
share, respectively, as presented in our Form 8-K for the ended October 3, 2025,
to $122.1 million, or $2.12 per diluted share, respectively, reflecting the
removal of a $18.1 million adjustment for inventory step-up in connection with
acquired businesses, resulting in a corresponding reduction to Adjusted net
income margin from continuing operations for the nine months ended October 3,
2025 from 8.1%, as presented in our Form 8-K for the period ended October 3,
2025, to 7.3%. There was no adjustment for inventory step-up during the three
months ended October 3, 2025 .
Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)
Three Octob… Octo… Nine Octo… Octob…
Mont… 2, 3, Months 2, 3,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
-Dol…
in
mill…
Net
inco… $ 3.4 $ -570… $ -6.1 $ -663.2
(los…
(GAA…
Net
inco…
(los… 0.6 % -104… % -0.4 % -39.7 %
marg…
(GAA…
Loss
(Inc…
from
disc… -2.2 — -2.2 0.3
oper…
net
of
taxes
Inco…
tax -1.7 4.0 15.9 13.0
expe…
(ben…
Other
(inc… -3.8 -0.4 -5.1 0.5
expe…
net
Inte…
expe… 7.6 8.8 24.8 27.3
net
Oper…
inco… $ 3.4 $ -558… $ 27.3 $ -622.1
(los…
(GAA…
Adju…
to
add:
Rest… 2.6 3.4 10.1 8.2
char…
MDR
and 0.9 2.4 2.8 9.0
other
cost…
Stra…
tran… 15.6 15.7 28.1 41.2
cost…
Stoc… 7.5 9.0 25.2 25.0
comp…
Depr…
and 30.2 30.7 91.2 88.9
other
amor…
Amor…
of 43.3 43.7 126.7 128.5
acqu…
inta…
Good…
impa… — 548.4 — 548.4
char…
Purc…
of — — — 45.8
roya…
inte…
Adju…
EBIT… $ 103.5 $ 94.8 $ 311.4 $ 273.0
(non…
Adju…
EBIT… 18.5 % 17.3 % 18.0 % 16.3 %
marg…
(non…
__________
(1) Restructuring charges reflect costs associated with the Company’s
restructuring programs to reduce the structural costs of the Company. For
further information, see Note 10, “Accrued Liabilities - Accrued Restructuring
Liability ” included in our Form 10-Q. Includes expenses of $1.5 million and
$1.7 million classified as Cost of sales on the Company’s Condensed Consolidated
Statements of Operations for the three and nine months ended October 3, 2025,
respectively. There were no similar charges for the three and nine months ended
October 2, 2026.
(2) MDR and other costs includes (i) $0.4 million and $1.6 million for the three
and nine months ended October 2, 2026 and $2.1 million and $7.6 million for the
three and nine months ended October 3, 2025, respectively, in non-recurring
costs specific to updating our quality system, product labeling, asset write-
offs and product remanufacturing to comply with the medical device reporting
regulations and other requirements of the new medical device regulations in the
European Union for devices which were introduced to the market prior to the
regulation and (ii) $0.5 million and $1.2 million for the three and nine months
ended October 2, 2026 and $0.4 million and $1.4 million for the three and nine
months ended October 3, 2025, respectively, of expenses to resolve certain
infrequent, non-recurring regulatory or other legal matters. These costs are
classified as Selling, general and administrative expense on our Condensed
Consolidated Statements of Operations.
(3) Strategic transaction costs includes: (i) $9.2 million and $21.0 million for
the three and nine months ended October 2, 2026 and $9.2 million and $28.1
million for the three and nine months ended October 3, 2025, respectively,
related to non-recurring integration costs associated with the Lima Acquisition
which includes (a) payroll and retention costs for roles eliminated in
connection with the integration of our recent acquisition of Lima where a legal
notice period was required prior to the employee’s separation from the Company,
or integration-related daily activities not related to former roles performed by
an employee during their legal notice period and prior to their separation from
the Company. In each case, such costs relate solely to roles eliminated in
connection with the integration of the Lima acquisition, and are non-recurring
and not part of our normal business operations; (b) professional and consulting
fees specifically incurred to consummate the acquisition and advise and
facilitate on post-acquisition integration matters including legal entity
consolidation, costs associated with rebranding and marketing acquired business
under Enovis name, such as marketing materials, trade show redesign costs and
product labeling; and (c) integration related costs associated with sales agent
and distributor network rationalization, including contract termination and
retention expenses, supply chain and portfolio integration, and quality
management system consolidation, (ii) $6.1 million and $6.5 million for the
three and nine months ended October 2, 2026 and $6.1 million and $11.8 million
for the three and nine months ended October 3, 2025, of non-recurring (non-Lima)
acquisition integration costs, and other non-recurring project costs for global
ERP rationalization and shared service center start-up, offset by a $5.7 million
non-cash gain in the second quarter of 2026 from the reversal of a portion of a
contingent consideration liability (See Note 11), and (iii) $0.3 million and
$0.6 million for the three and nine months ended October 2, 2026 and $0.4
million and $1.3 million for the three and nine months ended October 3, 2025,
respectively, related to the Separation of our former fabrication technology
business. These costs are classified as Selling, general and administrative
expense on our Condensed Consolidated Statements of Operations.
(4) Purchase of royalty interest represents the one-time, up-front expense
incurred by the Company to acquire the economic rights to future royalties under
product development agreements in connection with the termination of such
agreements as part of a strategic shift to a new product development model. The
Company believes that excluding the impact of such expense enhances
comparability between periods, provides investors with a clear and meaningful
view of our underlying business trends and aligns with how management evaluates
the ongoing business performance.
(5) In conjunction with our Form 10-Q filing for the first quarter of 2026, we
revised our definition of Adjusted EBITDA to no longer adjust for inventory
step-up charges. Adjusted EBITDA in prior periods has been revised to reflect
this change for consistency of presentation. Accordingly, Adjusted EBITDA for
the nine months ended October 3, 2025 has been revised from $291.1 million, as
presented in our Form 10-Q for the period ended October 3, 2025, to $273.0
million, reflecting the removal of a $18.1 million adjustment for inventory
step-up in connection with acquired businesses resulting in a corresponding
reduction to Adjusted EBITDA margin for the nine months ended October 3, 2025
from 17.4%, as presented in our Form 10-Q for the period ended October 3, 2025,
to 16.3%. There was no adjustment for inventory step-up during the three months
ended October 3, 2025 .
Enovis Corporation
Reconciliation of Gross Margin (GAAP) to Adjusted Gross Margin (non-GAAP)
Dollars in millions
(Unaudited)
Three Octob… Octo… Nine Octo… Octob…
Mont… 2, 3, Months 2, 3,
Ended 2026 2025 Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 558.7 $ 548.9 $ 1,73… $ 1,672…
sales
Gross $ 339.8 $ 328.9 $ 1,06… $ 995.8
prof…
Gross
prof… 60.8 % 59.9 % 61.5 % 59.5 %
marg…
(GAA…
Gross
prof… $ 339.8 $ 328.9 $ 1,06… $ 995.8
(GAA…
PPE
step… 0.6 0.6 1.7 1.6
depr…
Rest… — 1.5 — 1.7
char…
Adju…
gross $ 340.4 $ 331.0 $ 1,06… $ 999.2
prof…
(Non…
Adju…
gross
prof… 60.9 % 60.3 % 61.6 % 59.8 %
marg…
(Non…
__________
(1) In conjunction with our Form 10-Q filing for the first quarter of 2026, we
revised our definition of Adjusted gross profit to no longer adjust for
inventory step-up charges. Adjusted gross profit in prior periods has been
revised to reflect this change for consistency of presentation. Accordingly,
Adjusted gross profit for the nine months ended October 3, 2025 has been revised
from $1,017.3 million, as presented in our Form 8-K for the period ended October
3, 2025, to $999.2 million, reflecting the removal of a $18.1 million adjustment
for inventory step-up in connection with acquired businesses, resulting in a
corresponding reduction to Adjusted gross profit margin for the nine months
ended October 3, 2025 from 60.8%, as presented in our Form 8-K for the period
ended October 3, 2025, to 59.8%. There was no adjustment for inventory step-up
during the three months ended October 3, 2025 .
Enovis Corporation
Condensed Consolidated Balance Sheets
Dollars in thousands, except share amounts
(Unaudited)
October 2, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 13,038 $ 36,389
Trade receivables, less
allowance for 428,288 442,786
credit losses of $26,462 and
$25,609
Inventories, net 620,155 584,379
Prepaid expenses 48,602 42,283
Other current assets 137,493 101,222
Total current assets 1,247,576 1,207,059
Property, plant and equipment, 526,315 507,063
net
Goodwill 702,090 718,299
Intangible assets, net 1,093,942 1,236,713
Lease asset - right of use 74,714 72,256
Other assets 90,907 93,347
Total assets $ 3,735,544 $ 3,834,737
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Current portion of long-term $ 35,000 $ 35,000
debt
Accounts payable 200,449 187,531
Accrued liabilities 344,389 375,943
Total current liabilities 579,838 598,474
Long-term debt, less current 1,223,261 1,261,793
portion
Non-current lease liability 59,985 58,000
Other liabilities 376,877 424,568
Total liabilities 2,239,961 2,342,835
Equity:
Common stock, $0.001 par
value;
133,333,333 shares authorized;
57,694,452 and 57,194,781
shares issued 58 57
and outstanding as of October
2, 2026
and December 31, 2025,
respectively
Additional paid-in capital 3,073,646 3,048,414
Accumulated deficit -1,474,278 -1,467,463
Accumulated other -106,185 -91,363
comprehensive loss
Total Enovis Corporation 1,493,241 1,489,645
equity
Noncontrolling interest 2,342 2,257
Total equity 1,495,583 1,491,902
Total liabilities and equity $ 3,735,544 $ 3,834,737
Enovis Corporation
Condensed Consolidated Statements of Cash Flows
Dollars in thousands
(Unaudited)
Nine Months Ended October 2, 2026 October 3, 2025
──────────────────────────────────────────────────────────────────────────────
Cash flows from
operating
activities:
Net loss $ -6,069 $ -663,166
Adjustments to
reconcile net
loss to net
cash provided by
operating
activities:
Depreciation and 217,884 217,366
amortization
Impairment of — 548,442
goodwill
Stock-based
compensation 25,470 24,809
expense
Non-cash 5,929 5,120
interest expense
Fair value loss
on contingent — 1,787
acquisition
shares
Deferred income -42,241 -565
tax benefit
Loss on disposal
of property, 960 1,129
plant and
equipment
Changes in
operating assets
and
liabilities:
Trade 7,588 -17
receivables, net
Inventories, net -44,283 -33,153
Accounts payable 15,602 10,345
Other operating
assets and -10,364 16,652
liabilities
Net cash
provided by 170,476 128,749
operating
activities
Cash flows from
investing
activities:
Purchases of
property, plant
and -133,204 -141,122
equipment and
intangibles
Payments for
acquisitions,
net of cash -4,122 -26,859
received, and
investments
Cash received
(paid) for net
investment -3,283 1,601
hedge
derivatives
Net cash used in
investing -140,609 -166,380
activities
Cash flows from
financing
activities:
Repayments of
borrowings under -26,250 -15,000
term
credit facility
Proceeds from
borrowings on
revolving 172,000 177,000
credit
facilities and
other
Repayments of
borrowings on
revolving -189,041 -136,862
credit
facilities and
other
Payments of tax
withholding for -1,473 -3,504
stock-based
awards
Proceeds from
issuance of 1,354 1,318
common stock,
net
Deferred
consideration -9,637 -2,437
payments and
other
Net cash
provided by
(used in) -53,047 20,515
financing
activities
Effect of
foreign exchange
rates on Cash -171 2,566
and cash
equivalents
Decrease in Cash
and cash -23,351 -14,550
equivalents
Cash and cash
equivalents, 36,389 48,167
beginning of
period
Cash and cash
equivalents, end $ 13,038 $ 33,617
of period
Enovis Corporation
GAAP Net Sales and Growth Rate Summary - QTD
Dollars in millions
(Unaudited)
Thr…
Mon…
End…
Oct…
2, Con…
P… 2026 Oct… Cur… Org…
& (In 3, Gro… Gro… Gro…
R… mil… 2025 Rate Rat… Rat…
──────────────────────────────────────────────────────────────────────────────
U…
B… $ 13… $ 12… 4.5 % 4.5 % 4.5 %
&
S…
U…
O… 61… 71… -1… % -1… % 5.1 %
P…
I… 91… 92… -1… % -0… % -0… %
P…
T…
P… 28… 29… -1… % -1… % 3.0 %
&
R…
R…
U… 13… 12… 4.9 % 4.9 % 4.9 %
R…
I… 13… 12… 7.0 % 7.8 % 7.8 %
R…
T… 27… 25… 6.0 % 6.3 % 6.3 %
R…
T… $ 55… $ 54… 1.8 % 2.1 % 4.6 %
(1) Constant currency growth rate represents sales growth excluding the impact
of foreign exchange rate fluctuations based on prior year sales valued at the
current period foreign currency rates.
(2) Excludes the impact of foreign exchange rate fluctuations and
acquisitions/divestitures, thus providing a measure of change due to factors
such as price, product mix and volume.
(3) The three months ended October 3, 2025 include $13.8 million of sales from
the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions
product line
Enovis Corporation
GAAP Net Sales and Growth Rate Summary - YTD
Dollars in millions
(Unaudited)
Nine
Mon…
End…
Oct…
2, Con…
P… 2026 Oct… Cur… Org…
& (In 3, Gro… Gro… Gro…
R… mil… 2025 Rate Rat… Rat…
──────────────────────────────────────────────────────────────────────────────
U…
B… $ 37… $ 36… 3.4 % 3.4 % 3.4 %
&
S…
U…
O… 17… 20… -1… % -1… % 4.2 %
P…
I… 29… 28… 4.0 % 0.5 % 0.1 %
P…
T…
P… 84… 85… -1… % -2… % 2.5 %
&
R…
R…
U… 42… 39… 6.6 % 6.6 % 6.6 %
R…
I… 46… 42… 9.7 % 5.5 % 5.5 %
R…
T… 88… 81… 8.2 % 6.0 % 6.0 %
R…
T… $ 1,… $ 1,… 3.5 % 1.9 % 4.2 %
(1) Constant currency growth rate represents sales growth excluding the impact
of foreign exchange rate fluctuations based on prior year sales valued at the
current period foreign currency rates.
(2) Excludes the impact of foreign exchange rate fluctuations and
acquisitions/divestitures, thus providing a measure of change due to factors
such as price, product mix and volume.
(3) The nine months ended October 3, 2025 include $40.9 million of sales from
the October 2025 divestiture of the Company’s Dr. Comfort Footcare Solutions
product line.
Enovis Corporation
Change in Net Sales
Dollars in millions
(Unaudited)
N…
S…
P…
a… T…
R… R… E…
──────────────────────────────────────────────────────────────────────────────
$ C… $ C… $ C…
% % %
…
…
…
… $ 29… $ 25… $ 54…
…
…
…
…
…
…
…
… 8.7 3.0 % 16… 6.3 % 25… 4.6 %
…
… — — % — — % — — %
… -1… -4… % — — % -1… -2… %
…
… -0… -0… % -1… -0… % -1… -0… %
…
-5… -1… % 15… 6.0 % 9.8 1.8 %
…
…
…
… $ 28… $ 27… $ 55…
…
…
…
…
(1) Excludes the impact of foreign exchange rate fluctuations and
acquisitions/divestitures, thus providing a measure of change due to factors
such as price, product mix and volume.
(2) Represents the incremental sales as a result of acquisitions of businesses
for twelve months from the acquisition date. Excludes (i) acquisitions of former
distribution partners as such transactions primarily represent a shift from a
third-party distribution model to a direct sales model, and (ii) acquisitions of
intellectual property as such transactions involve the purchase of technologies
that have not been commercialized.
(3) Represents the decrease in sales as a result of divestitures of businesses
for twelve months from the divestiture date.
(4) Represents the difference between prior year sales valued at the actual
prior year foreign exchange rates and prior year sales valued at current year
foreign exchange rates.
Net
Sa…
Pr…
and To…
Re… Re… En…
──────────────────────────────────────────────────────────────────────────────
$ Ch… $ Ch… $ Ch…
% % %
…
…
…
… $ 8… $ 8… $ 1…
…
…
…
…
…
…
…
… 2… 2… % 4… 6… % 7… 4… %
…
… 1… 0… % — — % 1… 0… %
… -… -… % — — % -… -… %
…
… 9… 1… % 1… 2… % 2… 1… %
…
-… -… % 6… 8… % 5… 3… %
…
…
…
… $ 8… $ 8… $ 1…
…
…
…
…
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions,
thus providing a measure of change due to factors such as price, product mix and
volume.
(2) Represents the incremental sales as a result of acquisitions of businesses
for twelve months from the acquisition date. Excludes (i) acquisitions of former
distribution partners as such transactions primarily represent a shift from a
third-party distribution model to a direct sales model, and (ii) acquisitions of
intellectual property as such transactions involve the purchase of technologies
that have not been commercialized.
(3) Represents the decrease in sales as a result of divestitures of businesses
for twelve months from the divestiture date.
(4) Represents the difference between prior year sales valued at the actual
prior year foreign exchange rates and prior year sales valued at current year
foreign exchange rates.